Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

The CXCR4-CXCL12-Axis is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects in Vitro

Katrin Pansy
ORCID logo ,
Julia Feichtinger
,
Barbara Ehall
,
Barbara Uhl
,
Miriam Sedej
,
David Roula
,
Beata Pursche
,
Axel Wolf
,
Manuel Zoidl
,
Elisabeth Steinbauer
,
Verena Gruber
,
Hildegard Greinix
,
Katharina Prochazka
,
Gerhard Thallinger
,
Akos Heinemann
ORCID logo ,
Christine Beham-Schmid
,
Peter Neumeister
,
Tanja Wrodnigg
,
Karoline Fechter
,
Alexander Deutsch
* ORCID logo
Version 1 : Received: 30 July 2019 / Approved: 31 July 2019 / Online: 31 July 2019 (11:05:51 CEST)

A peer-reviewed article of this Preprint also exists.

Pansy, K.; Feichtinger, J.; Ehall, B.; Uhl, B.; Sedej, M.; Roula, D.; Pursche, B.; Wolf, A.; Zoidl, M.; Steinbauer, E.; Gruber, V.; Greinix, H.T.; Prochazka, K.T.; Thallinger, G.G.; Heinemann, A.; Beham-Schmid, C.; Neumeister, P.; Wrodnigg, T.M.; Fechter, K.; Deutsch, A.J. The CXCR4–CXCL12-Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro. Int. J. Mol. Sci. 2019, 20, 4740. Pansy, K.; Feichtinger, J.; Ehall, B.; Uhl, B.; Sedej, M.; Roula, D.; Pursche, B.; Wolf, A.; Zoidl, M.; Steinbauer, E.; Gruber, V.; Greinix, H.T.; Prochazka, K.T.; Thallinger, G.G.; Heinemann, A.; Beham-Schmid, C.; Neumeister, P.; Wrodnigg, T.M.; Fechter, K.; Deutsch, A.J. The CXCR4–CXCL12-Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro. Int. J. Mol. Sci. 2019, 20, 4740.

Abstract

In tumour cells of more than 20 different cancer types, the CXCR4-CXCL12-axis is involved in multiple key processes including proliferation, survival, migration, invasion, and metastasis. Since data on this axis in diffuse large B cell lymphoma (DLBCL) are inconsistent and limited, we comprehensively studied the CXCR4-CXCL12-axis in our DLBCL cohort as well as the effects of CXCR4 antagonists on lymphoma cell lines in vitro. In DLBCL, we observed a 140-fold higher CXCR4 expression compared to non-neoplastic controls. Interestingly, high expression of CXCR4 was associated with poor clinical outcome. Furthermore, in corresponding bone marrow biopsies, we observed a correlation of CXCL12 expression and lymphoma infiltration rate as well as a reduction of CXCR4 expression in remission of bone marrow involvement after treatment. Furthermore, the niacin derivate of the CXCR4 antagonist AMD070, which was synthesized by us, demonstrated stronger pro-apoptotic effects than AMD070 in vitro and induced expression of certain pro-apoptotic genes in CXCR4 positive lymphoma cell lines. Finally, WK1 treatment resulted in reduced expression of JNK-, ERK1/2- and NFκB/BCR-target genes. These data indicate that the CXCR4-CXCL12-axis impacts the pathogenesis of DLBCL and represents a potential therapeutic target in aggressive lymphomas.

Keywords

DLBCL; CXCR4-CXCL12-axis; CXCR4 antagonist

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.